Shu Wang

Tianjin University of Traditional Chinese Medicine — China

Medicine · Health Sciences

36h-index5.8kcitations292works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(17), Chronic Lymphocytic Leukemia Research(16), Phytochemical Studies and Bioactivities(14), Acute Lymphoblastic Leukemia research(11), Virus-based gene therapy research(9)

Publications292 total

TQB2440 compared with reference pertuzumab for HER2-positive, ER/PgR-negative, early or locally advanced breast cancer: a multicenter, randomized, double-blind, parallel-controlled, phase III equivalence trial
ESMO Open·2025Open Access
Minimizing Harm: Optimal Monitoring Boundaries When Harm is Present
Statistics in Biopharmaceutical Research·2025
The impact of triglyceride-glucose-related obesity indices and sleep patterns on accelerated aging: evidence from NHANES 2005-2018
HORMONES·2025· 1 cited
[Clinical application effects of indocyanine green angiography combined with color Doppler ultrasound in perforator localization of anterolateral thigh perforator flaps].
PubMed·2025
Single cell RNA sequencing reveals a dysbalance of proinflammatory vs. immunosuppressive dendritic cells in mouse and human aortic aneurysms
Frontiers in Cardiovascular Medicine·2025Open Access
Progression and influencing factors of knee osteoarthritis based on a multi-state Markov model: Data from OAI
Osteoarthritis and Cartilage Open·2025· 1 citedOpen Access
Supplementary Table S2 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025Open Access
Supplementary Figure S6 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025Open Access
Supplementary Table S4 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025Open Access
Supplementary Table S3 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025Open Access
Supplementary Figure S2 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025Open Access
Supplementary Figure S1 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025Open Access
Supplementary Figure S3 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025Open Access
Supplementary Table S6 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025Open Access
Data from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025Open Access
Supplementary Figure S5 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025Open Access
Supplementary Figure S4 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025Open Access
Supplementary Table S5 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025Open Access
Supplementary Table S7 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025Open Access
Supplementary Table S1 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025Open Access
page 1 of 15Next →

Frequent Co-authors

John A. Kellum(5), Derek C. Angus(4), Dongdong Wang(4), Donald M. Yealy(3), Yong Feng(3), David T. Huang(2), Sachin Yende(2), Ruiyue Yang(2), Jun Dong(2), Hongxia Li(2), Hanbang Guo(2), Wenxiang Chen(2), Priyanka Priyanka(2), A.J. Conrad Smith(2), Kai Singbartl(2), Paul M. Palevsky(2), Lakhmir S. Chawla(2), Lisa M. Greene(2), Seema M. Nathwani(2), Azizah M. Malebari(2)